Expert Opinions On DCTs In 2024, How To Measure Trial Diversity Improvement & More
Clinical Leader
A resource and forum to investigate and resolve the common struggles related to running effective clinical trials.
Welcome to the Clinical Trial Insights newsletter, featuring strategic insights and expert opinions on designing and running clinical trials. Each edition covers the latest trending articles on ClinicalLeader.com.
In this week's issue, we'll explore what experts think will happen with DCTs in 2024, how to measure progress in improving trial diversity, takeaways to consider for ensuring clinical data integrity, anticipated trends for the clinical supply chain market, and other popular insights.
If you like what you're seeing in our condensed LinkedIn editions, subscribe to our daily newsletter for full access to exclusive articles, webinars, e-books, and more! Subscribe Now →
Reserve Your Spot For Clinical Leader Live!
January 18th @ 11AM EST
THIS WEEK! Join us on Thursday for our next Clinical Leader Live virtual event. Our expert panel will discuss their firsthand experiences — and possible future applications — with AI in everything from protocol design to numerous clinops activities.
TOP 5 READS OF THE PAST WEEK
Heading into 2024, as with any annual flip of the calendar, we anticipate there will be topics of conversation that will fade away, persist, and develop — in the clinical trials industry as in life. In part three of this preview of clinical trial trends, experts discuss the state of decentralized trials in all their permutations and muse on their fates as 2024 begins.
In the world of institutional review boards (IRBs), some measurements can be easily ascertained, while other aspects of IRB quality and effectiveness are more difficult to quantify. Advarra 's Julie Ozier and Emily Eldh explore the challenges of defining and measuring a “quality” IRB review and discuss certain key efforts by research community stakeholders to overcome such obstacles.
Recommended by LinkedIn
In this article, learn about the Clinical Trials Transformation Initiative (CTTI)'s Diversity Project that makes recommendations for more diverse clinical trials and presents a maturity model to help sponsors develop or improve sustained clinical trial research infrastructure.
Companies are faced with new challenges to maintain data integrity in the disparate ecosystem of data sources. Halloran Consulting Group, Inc. provides three key takeaways to consider for protocol preparation and navigating disruptions mid-stream to ensure the integrity of clinical data.
Recent advancements in technology, rising costs, high rates of trial failures, and the rise of patient-centric trials have had a substantial impact on the clinical trial supplies market. Explore some of the anticipated developments and trends for the clinical trial supply chain in this article from Clinical Supply Leader.
MORE TO EXPLORE
Clinical Leader is an online community serving professionals in the clinical research space. We share insights and best practices — from industry experts — to help sponsors and CROs tackle the biggest challenges they face in designing and running clinical trials.
To get the most out of our offerings, join the Clinical Leader community.